Longeveron (LGVN) stock forecast for 2022
Last update: January 27, 2023 (05:32)
Sector: HealthcareThe share price of Longeveron Inc. (LGVN) now
50/200 Day Moving Average: $3.593 / $5.54
This figure corresponds to the Average Price over the previous 50/200 days. For Longeveron stocks, the 50-day moving average is the resistance level today.
For Longeveron stocks, the 200-day moving average is the resistance level today.
Are you interested in Longeveron stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Longeveron stock price in 2022. How much will one Longeveron share be worth in 2022? Is it worth taking profit / loss on Longeveron stock now or waiting? What are analysts' forecasts for Longeveron stock?
We forecast Longeveron stock performance using neural networks based on historical data on Longeveron stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. The Longeveron stock prediction results are shown below and presented as a graph, table and text information.
Longeveron stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Longeveron analysts is $15.5.
Today 200 Day Moving Average is the resistance level (5.54 $).
50 Day Moving Average is the resistance level (3.593 $).
Historical and forecast chart of Longeveron stock
The chart below shows the historical price of Longeveron stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Longeveron stock price can be found in the table below.
Longeveron (LGVN) Forecast for 2022
| Month | Target | Pes. | Opt. | Vol., % |
|---|
Longeveron information and performance
Longeveron LLC is a clinical stage biotechnology company that engages in the development of cellular therapies for specific aging-related and life-threatening conditions. Its lead product, LOMECEL-B, is a cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. The company was founded by Joshua M. Hare and Donald M. Soffers in October 9, 2014 and is headquartered in Miami, FL.
1951 NW 7TH AVENUE, SUITE 520, MIAMI, FL, US
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.